MARKET WIREYahoo Finance • 6h ago
3 Reasons to avoid NATR and 1 stock to buy insteadYahoo Finance report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
Why NATR Stock slipped -0.24% Today — RQD Quant Desk Flash
$12.25 -0.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $12.22
Nature's Sunshine Products Inc. (NATR) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C+ • HOLD / WATCH
Cap $216.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NATR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NATR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Nature's Sunshine Products Inc. (NASDAQ: NATR) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $12.25 (-0.24% 1D, market cap $216.1M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, NATR ranks #103 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NATR compare to BBOT and KRRO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NATR carries a Roarable C+ (68/100 RQD), trailing P/E of 11.1x, gross margin of 72.4%, and ROIC of 28.9%. By comparison, BBOT (BridgeBio Oncology Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $216.5M) and KRRO (Korro Bio Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $209.1M). Among the 5-stock peer group, NATR leads on earnings multiple (11.1x) while KROS leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NATR?
▼
Per NATR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000275053), Nature's Sunshine Products Inc. generated $480.1M in revenue (+5.7% YoY), $19.5M in net income, and $28.8M in free cash flow against $261.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $12.22 (-0.23%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 6% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C+ · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+4.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NATR)Realized 20D OHLCV Swing Band: ±6.4%
Deterministic 5-Pillar Attribution (68/100 Composite)
🔍 WHY NATR SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (26% of score)
SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)
▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 6% FCF Margin ($28.8M FCF) & 72.4% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B+$12.71-1.3% Next Q
76
Q2 (-2Q)Grade B$12.55-2.2% Next Q
73
Q3 (-1Q)Grade B$12.27-0.2% Next Q
71
CurrentGrade C+$12.25+1.8% Hist 90D α
68
Trajectory: B+ (76) → C+ (68)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the NATR Bull Thesis Could Fail
Even with a 68/100 (C+) score, NATR faces multiple-compression risk if 11.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 69.9% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($13.04) or 200D SMA ($20.50) invalidates the momentum regime and cuts Target Base ($12.80) toward Bear Floor ($9.98).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NATR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NATR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NATR Stock slipped -0.24% Today — RQD Quant Desk Flash
Nature's Sunshine Products Inc. (NATR) slipped -0.24% to $12.25, trading at 2% of its 52-week range ($12 – $28.14). Solid 72% profit margin (29% return on capital), mixed timing at 11x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 2% of its 52-week range ($12 – $28.14) with RSI-14 at 41.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.4% around $12.25 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 72.4% gross margin and $28.8M annual free cash flow.
Live NATR Headlines & Catalysts
MARKET WIRETradingView • 9h ago
Nature's Sunshine Products, Inc. Estimates – NASDAQ:NATRTradingView report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 12h ago
Nature’s Sunshine Sets Third Quarter 2026 Conference Call for Wednesday, November 4, 2026, at 5:00 p.m. ETYahoo Finance report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 15h ago
Nature's Sunshine Products (NATR) Edges Higher as Shares Hold Above $12.50 - Conversion Tradehttps://www.siam.in/ report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Traders Daily • 18h ago
(NATR) Risk Channels and Responsive AllocationStock Traders Daily report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingKey • 21h ago
Top U.S. Stock Gainers: Biggest Price IncreasesTradingKey report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Nature's Sunshine Products (NATR) Edges Higher to $12.71 as Buyers Hold the Line Above Support - Continuation Pattern Pickshttps://www.siam.in/ report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Most Active Stocks Today: U.S. MarketTradingKey report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 3d ago
Canaccord Genuity Maintains Buy on Natures Sunshine Products, Lowers Price Target to $25Canaccord Genuity analyst Susan Anderson maintains Natures Sunshine Products (NASDAQ:NATR) with a Buy and lowers the price target from $36 to $25.
MARKET WIREYahoo • 14d ago
3 Out-of-Favor Stocks We Keep Off Our RadarHitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (NATR Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NATR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.94%▲ RESISTANCE BREAKOUT
2026-11-02O $12.27H $12.55L $12.25C $12.25VOL 13.3K
RES: $11.09SUP: $11.39SMA50: $13.04SMA200: $20.50
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NATR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
0.9%/yr Implied 5Y Growth
vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NATR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NATR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NATR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NATR)
Health Care Rank #103 of 1016
⚔️ BBOT vs NATR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NATR vs. BBOT, KRRO, SLGL, KROS)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Nature's Sunshine Products Inc. (NATR) ranks #103 by composite RQD confidence (68/100, grade C+) and #564 by equity capitalization ($216.1M). Within this direct 5-issuer industry benchmark cohort, NATR leads on earnings valuation at 11.1x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. NATR currently leads its immediate peer cohort in composite quantitative strength at 68/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NATR
ACTIVE
Nature's Sunshine Products Inc. | C+ | 68/100 | 11.1x | 72.4% | 28.9% | -0.24% | $216.1M | Benchmark Subject |
| BBOT BridgeBio Oncology Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -2.96% | $216.5M | /bbot-vs-natr → |
| KRRO Korro Bio Inc. | D | 44/100 | — | — | -35.0% | +0.81% | $209.1M | /krro-vs-natr → |
| SLGL Sol-Gel Technologies Ltd. | D+ | 54/100 | — | — | -35.0% | -0.45% | $224.8M | /slgl-vs-natr → |
| KROS Keros Therapeutics Inc. | C+ | 66/100 | — | — | 85.0% | -2.82% | $225.2M | /kros-vs-natr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000275053In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nature's Sunshine Products Inc. (NATR) reported GAAP revenue of $480.1M (+5.7% vs. FY2024 revenue of $454.4M , and +7.8% cumulative change since FY2023) , GAAP net income of $19.5M, operating cash flow of $35.3M, and free cash flow of $28.8M (+101.3% YoY). On the balance sheet, NATR closed FY2025 with $261.1M in total assets against $0 in total debt (Altman Z-Score: 4.33, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $480.1M | $19.5M | $35.3M | $28.8M | $261.1M | — |
| FY2024 (FY) | 2024-12-31 | $454.4M | $7.7M | $25.3M | $14.3M | $240.9M | — |
| FY2023 (FY) | 2023-12-31 | $445.3M | $15.1M | $41.2M | $41.2M | — | — |
3. NATR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NATR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Nature's Sunshine Products Inc. (NASDAQ: NATR) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $12.25 (-0.24% 1D, market cap $216.1M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, NATR ranks #103 in composite RQD confidence.
How does NATR compare to BBOT and KRRO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NATR carries a Roarable C+ (68/100 RQD), trailing P/E of 11.1x, gross margin of 72.4%, and ROIC of 28.9%. By comparison, BBOT (BridgeBio Oncology Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $216.5M) and KRRO (Korro Bio Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $209.1M). Among the 5-stock peer group, NATR leads on earnings multiple (11.1x) while KROS leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NATR?
Per NATR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000275053), Nature's Sunshine Products Inc. generated $480.1M in revenue (+5.7% YoY), $19.5M in net income, and $28.8M in free cash flow against $261.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NATR trading relative to its 50-day, 200-day, and 52-week technical levels?
NATR last traded at $12.25 (-0.24% on volume of 99,356 shares), positioning the stock -6.06% below its 50-day simple moving average ($13.04) and -40.24% below its 200-day simple moving average ($20.50). Across its 52-week range of $12.00 to $28.14, NATR sits at the 1.5% percentile with a 14-day RSI of 41.8 (NEUTRAL RANGE) and an implied next-earnings move of ±6.4% ($11.47 to $13.03).
NATR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NATR stock moving today?
Why NATR Stock slipped -0.24% Today — RQD Quant Desk Flash. Solid 72% profit margin (29% return on capital), mixed timing at 11x P/E—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 68/100 (C+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
NATR — Nature's Sunshine Products Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:40:48Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD rating assigns NATR a score of 68 and a letter grade of C+, with a verdict label of "Roarable Hold — Upper Neutral / Watch for Breakout" (per the Roarable RQD rating). Across the five pillars:
- Fundamental cash engine (16 / 20): The rating cites ROIC of 28.9% and an FCF yield of 13.35% (per the Roarable RQD rating and market data). This is the strongest contributor to the score and suggests the business generates meaningful returns on invested capital relative to its market value.
- Whale 13F flow (6 / 20): Institutional accumulation and options positioning score low. Per the source, the holders section is empty, so the basis for this weak score cannot be verified from the supplied material.
- Insider conviction (18 / 20): The highest pillar, reflecting SEC Form 4 and Congressional PTR cluster flow (per the Roarable RQD rating). The underlying transaction detail is not provided in the source data.
- Macro regime fit (12 / 20): Beta of 1.0 and sector sensitivity are cited (per the Roarable RQD rating and market data). A beta of 1.0 implies market-level sensitivity, not a defensive or aggressive profile.
- Forensic balance sheet (16 / 20): Altman Z-Score of 4.33, Piotroski F-Score of 8/9, and Debt/Equity of 0.5 (per the Roarable RQD rating).
For a prospective investor, the upside case rests on the cash-generation metrics and the strong balance-sheet pillar, against valuation that appears low on the market data (P/E TTM of 11.1, EV/EBITDA of 4). The tradeoffs are thin operating margin (5.2%), weak institutional flow, and a verdict that stops short of a buy signal. The "Watch for Breakout" label indicates the rating is conditional on future confirmation rather than already triggered.
Snapshot
Business
Nature's Sunshine Products Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The source data does not describe its products, customers, or revenue model. Market capitalization is reported as $0.2B (per the company profile). Gross margin is 72.4% (per market data), indicating the reported business carries a high gross margin profile.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $480.1M | $24.7M | $19.5M | N/A | $28.8M | $93.9M | N/A |
| FY 2024 | $454.4M | $20.1M | $7.7M | N/A | $14.3M | $84.7M | N/A |
| FY 2023 | $445.3M | $18.7M | $15.1M | N/A | $41.2M | N/A | N/A |
Revenue rose from $445.3M (FY 2023) to $480.1M (FY 2025) per the SEC financials. Net income was $19.5M in FY 2025, up from $7.7M in FY 2024 but below $15.1M in FY 2023 in the earlier year's terms of comparison. Reported operating margin is 5.2% and net margin is 4.1% (per market data). ROIC is 28.9% and the Altman Z-Score is 4.33 with a Piotroski F-Score of 8/9 (per the Roarable RQD rating). Debt/Equity of 0.5 is cited (per the Roarable RQD rating); the debt figures themselves are not available in source data.
Recent Catalysts & News Wire Analysis
Five news items are provided (per the recent news section):
- Yahoo Finance (YELLOW, MARKET WIRE): "3 Reasons to avoid NATR and 1 stock to buy instead." The article body is not included in the source data.
- TradingView (YELLOW, MARKET WIRE): "Nature's Sunshine Products, Inc. Estimates." Body not provided.
- Yahoo Finance (YELLOW, MARKET WIRE): Announces a third-quarter 2026 conference call for Wednesday, November 4, 2026, at 5:00 p.m. ET. This is the only dated company event in the source data.
- Stock Traders Daily (RED, RISK WATCH): "(NATR) Risk Channels and Responsive Allocation." Flagged as a risk watch item; body not provided.
- TradingKey (GREEN, CATALYST): "Top U.S. Stock Gainers: Biggest Price Increases," flagged as a catalyst. Body not provided.
A separate item carries a summary reporting shares holding above $12.50, but its headline and summary text are not corroborated by the price data (price is 12.42). The butterfly supply-chain graph reports no links and no proprietary signals (per the Butterfly Supply-Chain Graph).
Open Questions
- What drives the FY 2024 net income low ($7.7M) relative to operating income ($20.1M), and what explains the FY 2025 recovery?
- What is the company's total debt and cash position, given that debt is not reported in the source data?
- What are the EPS figures for each reported period, since EPS is listed as N/A across all three filings?
- What insider and institutional transactions underlie the insider (18/20) and whale-flow (6/20) pillar scores?
- What is the content of the third-quarter 2026 results expected on November 4, 2026?
NATR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Nature's Sunshine Products Inc. (NATR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 6h ago
3 Reasons to avoid NATR and 1 stock to buy instead Yahoo Finance report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 9h ago
Nature's Sunshine Products, Inc. Estimates – NASDAQ:NATR TradingView report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 12h ago
Nature’s Sunshine Sets Third Quarter 2026 Conference Call for Wednesday, November 4, 2026, at 5:00 p.m. ET Yahoo Finance report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 15h ago
Nature's Sunshine Products (NATR) Edges Higher as Shares Hold Above $12.50 - Conversion Trade https://www.siam.in/ report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Traders Daily • 18h ago
(NATR) Risk Channels and Responsive Allocation Stock Traders Daily report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingKey • 21h ago
Top U.S. Stock Gainers: Biggest Price Increases TradingKey report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Nature's Sunshine Products (NATR) Edges Higher to $12.71 as Buyers Hold the Line Above Support - Continuation Pattern Picks https://www.siam.in/ report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Most Active Stocks Today: U.S. Market TradingKey report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NATR Bull vs. Bear Conversation Board — What's Your Call at $12.25?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NATR 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $13.26 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is NATR (C+ • RQD 68/100) a Buy at $12.28?
Welcome to the NATR (Nature's Sunshine Products Inc.) Roar Pit. Current RQD Composite is 68/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (28.9% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $10.07 (-18.0%)
Spot @ $12.28 Pump the brakes on NATR — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on NATR, but look at what you are paying: 11.1x trailing P/E with 72.4% gross margins. Unless Nature's Sunshine Products Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $15.47 (+26.0%)
Spot @ $12.28 NATR cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on NATR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $12.28 (52-wk range $11.31 - $14.01), any beat on forward guidance forces shorts and underweight funds to chase.